| Latest Elan News Headlines |
| Date | Time | Source | |
| 09/17/2009 | 9:00AM | PRNUS | Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equi
NEW BRUNSWICK, N.J. and DUBLIN, Sept. 17 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) and Elan Corporation plc (NYSE:ELN) today announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan... More...>> |
| 07/31/2009 | 5:18PM | PRNUS | FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
INVEGA(R) SUSTENNA(TM) is the First Once-Monthly Atypical Antipsychotic Approved for Schizophrenia in the United States
TITUSVILLE, N.J., July 31 /PRNewswire/ -- The U.S. Food and Drug Administration today approved INVEGA SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and... More...>> |
| 07/14/2009 | 9:00AM | PRNUS | Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Asso
VIENNA, Austria, July 14 /PRNewswire-FirstCall/ -- Elan Corporation, plc (NYSE:ELN) and Wyeth (NYSE:WYE) presented information this week at the Alzheimer Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) from seven posters and one podium presentation about the growing burden of care and costs... More...>> |
| 07/02/2009 | 7:57AM | PRNUS | Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Invest
First-in-Class Alzheimer's Treatments Expand Existing J&J Neuroscience Pipeline Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan
NEW BRUNSWICK, N.J. and DUBLIN, July 2 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) and Elan Corporation plc (NYSE:ELN) today announced a definitive agreement... More...>> |
| 07/02/2009 | 7:57AM | PRNUS | Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Invest
First-in-Class Alzheimer's Treatments Expand Existing J&J Neuroscience Pipeline Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan
NEW BRUNSWICK, N.J. and DUBLIN, July 2 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) and Elan Corporation plc (NYSE:ELN) today announced a definitive agreement... More...>> |
| 02/06/2009 | 10:37AM | PRNUS | Seven Summits Research Releases Comments on BAC, FCX, CRM, DKS, and ELN
CHICAGO, Feb. 6 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at: http://www.go7now.com/nb/0206X (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 01/13/2009 | 10:26AM | PRNUS | Seven Summits Research Releases Comments on BAC, WLP, ELN, LXK, and MAC
CHICAGO, Jan. 13 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/0113X (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 01/07/2009 | 6:50AM | PRNUS | Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent
NEW YORK, Jan. 7 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC:ILNS) (BULLETIN BOARD: ILNS) , a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced today that it has granted a non-exclusive License... More...>> |
| 12/19/2008 | 8:04AM | PRNUS | AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide
LONDON and MOUNTAIN VIEW, Calif., Dec. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) and MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) announced today an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulized formulation of budesonide. UDB is... More...>> |
| 12/18/2008 | 8:00AM | PRNUS | Jazz Pharmaceuticals Announces Issuance of Key Patent for Once-A-Day LUVOX CR(R)
PALO ALTO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,465,462 covering its Once-A-Day LUVOX CR(R) (fluvoxamine maleate) Extended-Release Capsule product. The patent was assigned to Elan Pharma... More...>> |
| 12/11/2008 | 4:38PM | PRNUS | Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
RADNOR, Pa., Dec. 11 /PRNewswire/ -- The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP:
Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of purchasers of the securities... More...>> |
| 11/12/2008 | 8:00AM | PRNUS | US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning P
Data indicate Focalin XR provides rapid and significant improvements in attention, behavior and academic productivity at 30 minutes post-dose
EAST HANOVER, N.J., Nov. 12 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved a 30-minute onset of action for Focalin(R) XR (dexmethylphenidate HCl) extended-release... More...>> |
| 10/24/2008 | 10:21AM | PRNUS | Seven Summits Research Releases Comments on PEP, ORCL, VZ, LVS, and ELN
CHICAGO, Oct. 24 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/1024Y (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 08/26/2008 | 9:31AM | PRNUS | Seven Summits Research Releases Alerts on AAPL, FSLR, MET, UNH, and ELN
CHICAGO, Aug. 26 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks.
Seven Summits Strategic Investments' PriceWatch Alerts are available at
http://www.iotogo.com/s/082608A (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's PriceWatch Alerts cover... More...>> |
| 08/20/2008 | 8:45AM | PRNUS | Alzheimer's Disease and Emerging Treatments Analyzed in Neurotech Insights
SAN FRANCISCO, Aug. 20 /PRNewswire/ -- Emerging therapeutic strategies for Alzheimer's disease is the focus of the most recent edition of Neurotech Insights, the leading monthly industry newsletter covering drugs, devices and diagnostics for the brain and nervous system.
This month's feature article reviews the competing... More...>> |
| 08/18/2008 | 10:20AM | PRNUS | BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
DALLAS, Aug. 18 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's Trade Alerts include: Elan Corp. plc (NYSE:ELN), Pfizer Inc. (NYSE:PFE), Amgen Inc... More...>> |
| 07/15/2008 | 9:31AM | PRNUS | Seven Summits Research Releases Alerts on BAC, SLB, MOS, ELN, and NMX
CHICAGO, July 15 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks.
Seven Summits Strategic Investments' PriceWatch Alerts are available at
http://www.iotogo.com/s/071508A (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's PriceWatch Alerts cover... More...>> |
| 07/08/2008 | 8:00AM | PRNUS | Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD P
- Focalin XR demonstrated better symptom control versus Concerta from 30 minutes to six hours post-dose in primary and secondary endpoints
EAST HANOVER, N.J., July 8 /PRNewswire/ -- A head-to-head study, published in the June Journal of Child and Adolescent Psychopharmacology, confirms that Focalin(R) XR (dexmethylphenidate... More...>> |
| 04/14/2008 | 8:00AM | PRNUS | Jazz Pharmaceuticals' LUVOX CR Is Now Available for Patients With Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorde
PALO ALTO, Calif., April 14 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) announced today that Once-A-Day LUVOX(R) CR (fluvoxamine maleate) Extended-Release Capsules is now available at pharmacies throughout the United States. LUVOX CR was recently approved by the U.S. Food and Drug Administration... More...>> |
| 08/01/2007 | 3:49PM | PRNUS | The Michael J. Fox Foundation for Parkinson's Research Announces $1.2 Million in Funding to Advance Development of Drug Targets
NEW YORK, Aug. 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced $1.2 million in total awards to four research teams working to advance potentially disease-modifying therapeutic targets for PD along the drug development pipeline. The funding was awarded under the Novel... More...>> |